Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognostic utility of tumor grade and IDH-mutation status for immunotherapy response in high grade glioma: a systematic review and meta-analysis.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia - 1 Oct 2026

Srinivasan Srivats, Eraghi Mohammad Mirahmadi, Odiase Peace, Mazumder Snehal, Ahuja Aksheen, Ranganathan Sruthi, Patel Parth, O'Leary Sean, Guirguis Mina, Barrie Umaru, Sun Matthew Z, Patel Ankur

Abstract excerpt

INTRODUCTION: Survival outcomes among patients with World Health Organization grade III gliomas and IDH-mutant (IDHmt) gliomas treated with immunotherapy (IT) remain understudied, with most research focusing on grade IV (G4) glioblastomas or IDH wild-type (IDHwt) tumors. METHODS: A systematic literature search was conducted in PubMed/MEDLINE, SCOPUS, Embase, Google Scholar, and Science Direct databases following...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Glioma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunotherapy

Share to Isocitrate Dehydrogenase

Share to Mutation

Share to Neoplasm Grading

Share to Prognosis

Source

Identifiers

PMID: 42475978
DOI: 10.1016/j.jocn.2026.112202

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostic utility of tumor grade and IDH-mutation status for immunotherapy response in high grade glioma: a systematic review and meta-analysis.PMID 42475978Read ↗

Molecular and Clinical Determinants of Response to Immunotherapy in High-Grade GliomaSemantic proximity Read ↗

IDH wild-type lower-grade gliomas with glioblastoma molecular features: a systematic review and meta-analysis.Semantic proximity Read ↗

A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy.Semantic proximity Read ↗

The prognosis of gliomas with different molecular subtypes in the era of intensity-modulated radiation therapy (IMRT).Semantic proximity Read ↗

Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.Semantic proximity Read ↗

Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.Semantic proximity Read ↗

The survival outcomes of molecular glioblastoma IDH-wildtype: a multicenter study.Semantic proximity Read ↗

Novel interferon-gamma-related 2-gene signature predicts outcome and responsiveness to immune checkpoint blockade in gliomaSemantic proximity Read ↗

Long-term outcomes in IDH-wildtype (IDH-wt) gliomas with historical WHO grade 2 and 3 histology.Semantic proximity Read ↗

Molecularly diagnosed glioblastoma: clinical presentation and outcomes.Semantic proximity Read ↗

Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy.Semantic proximity Read ↗

Overview of prognostic factors in adult glioma; a 10-year experience at a single institutionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.